190 related articles for article (PubMed ID: 26608890)
1. The ELF Honest Data Broker: informatics enabling public-private collaboration in a precompetitive arena.
Paillard G; Cochrane P; Jones PS; van Hoorn WP; Caracoti A; van Vlijmen H; Pannifer AD
Drug Discov Today; 2016 Jan; 21(1):97-102. PubMed ID: 26608890
[TBL] [Abstract][Full Text] [Related]
2. The European Lead Factory: Results from a decade of collaborative, public-private, drug discovery programs.
van Vlijmen H; Pannifer AD; Cochrane P; Basting D; Li VM; Engkvist O; Ortholand JY; Wagener M; Duffy J; Finsinger D; Davis J; van Helden SP; de Vlieger JSB;
Drug Discov Today; 2024 Mar; 29(3):103886. PubMed ID: 38244673
[TBL] [Abstract][Full Text] [Related]
3. How informatics can potentiate precompetitive open-source collaboration to jump-start drug discovery and development.
Perakslis ED; Van Dam J; Szalma S
Clin Pharmacol Ther; 2010 May; 87(5):614-6. PubMed ID: 20376001
[No Abstract] [Full Text] [Related]
4. The Joint European Compound Library: boosting precompetitive research.
Besnard J; Jones PS; Hopkins AL; Pannifer AD
Drug Discov Today; 2015 Feb; 20(2):181-6. PubMed ID: 25205347
[TBL] [Abstract][Full Text] [Related]
5. Translation of innovative chemistry into screening libraries: an exemplar partnership from the European Lead Factory.
Morgentin R; Dow M; Aimon A; Karageorgis G; Kalliokoski T; Roche D; Marsden S; Nelson A
Drug Discov Today; 2018 Sep; 23(9):1578-1583. PubMed ID: 29753124
[TBL] [Abstract][Full Text] [Related]
6. The European Lead Factory: An updated HTS compound library for innovative drug discovery.
van Vlijmen H; Ortholand JY; Li VM; de Vlieger JSB
Drug Discov Today; 2021 Oct; 26(10):2406-2413. PubMed ID: 33892142
[TBL] [Abstract][Full Text] [Related]
7. Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective.
Karawajczyk A; Giordanetto F; Benningshof J; Hamza D; Kalliokoski T; Pouwer K; Morgentin R; Nelson A; Müller G; Piechot A; Tzalis D
Drug Discov Today; 2015 Nov; 20(11):1310-6. PubMed ID: 26429298
[TBL] [Abstract][Full Text] [Related]
8. Four disruptive strategies for removing drug discovery bottlenecks.
Ekins S; Waller CL; Bradley MP; Clark AM; Williams AJ
Drug Discov Today; 2013 Mar; 18(5-6):265-71. PubMed ID: 23098820
[TBL] [Abstract][Full Text] [Related]
9. Patent-free pact pushes the boundaries of precompetitive research.
Dolgin E
Nat Med; 2014 Jun; 20(6):564-5. PubMed ID: 24901552
[No Abstract] [Full Text] [Related]
10. Hit Discovery for Public Target Programs in the European Lead Factory: Experiences and Output from Assay Development and Ultra-High-Throughput Screening.
Honarnejad S; van Boeckel S; van den Hurk H; van Helden S
SLAS Discov; 2021 Feb; 26(2):192-204. PubMed ID: 32734803
[TBL] [Abstract][Full Text] [Related]
11. Precompetitive activity to address the biological data needs of drug discovery.
Sidders B; Brockel C; Gutteridge A; Harland L; Jansen PG; McEwen R; Michalovich D; Seidel H; Weiss B; Williams-Jones B; Woodwark M
Nat Rev Drug Discov; 2014 Feb; 13(2):83-4. PubMed ID: 24481293
[No Abstract] [Full Text] [Related]
12. Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
Page T; Dubina H; Fillipi G; Guidat R; Patnaik S; Poechlauer P; Shering P; Guinn M; Mcdonnell P; Johnston C
J Pharm Sci; 2015 Mar; 104(3):821-31. PubMed ID: 25448273
[TBL] [Abstract][Full Text] [Related]
13. Pharmacotherapy crisis in the spotlight--is open collaboration between academia and industry the answer?
Kaski JC
Cardiovasc Drugs Ther; 2011 Apr; 25(2):187-8. PubMed ID: 21503624
[No Abstract] [Full Text] [Related]
14. Using Microscale Thermophoresis to Characterize Hits from High-Throughput Screening: A European Lead Factory Perspective.
Rainard JM; Pandarakalam GC; McElroy SP
SLAS Discov; 2018 Mar; 23(3):225-241. PubMed ID: 29460707
[TBL] [Abstract][Full Text] [Related]
15. Academic drug discovery: current status and prospects.
Everett JR
Expert Opin Drug Discov; 2015; 10(9):937-44. PubMed ID: 26088126
[TBL] [Abstract][Full Text] [Related]
16. UCLA's Molecular Screening Shared Resource: enhancing small molecule discovery with functional genomics and new technology.
Damoiseaux R
Comb Chem High Throughput Screen; 2014 May; 17(4):356-68. PubMed ID: 24661210
[TBL] [Abstract][Full Text] [Related]
17. Novel web-based tools combining chemistry informatics, biology and social networks for drug discovery.
Hohman M; Gregory K; Chibale K; Smith PJ; Ekins S; Bunin B
Drug Discov Today; 2009 Mar; 14(5-6):261-70. PubMed ID: 19231313
[TBL] [Abstract][Full Text] [Related]
18. The University of Kansas High-Throughput Screening Laboratory. Part II: enabling collaborative drug-discovery partnerships through cutting-edge screening technology.
McDonald PR; Roy A; Chaguturu R
Future Med Chem; 2011 Jul; 3(9):1101-10. PubMed ID: 21806374
[TBL] [Abstract][Full Text] [Related]
19. The innovative medicines initiative: a European response to the innovation challenge.
Goldman M
Clin Pharmacol Ther; 2012 Mar; 91(3):418-25. PubMed ID: 22318619
[TBL] [Abstract][Full Text] [Related]
20. The Drug Discovery Portal: a resource to enhance drug discovery from academia.
Clark RL; Johnston BF; Mackay SP; Breslin CJ; Robertson MN; Harvey AL
Drug Discov Today; 2010 Aug; 15(15-16):679-83. PubMed ID: 20547242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
